| SC 13G | 2017-02-14 | BAKER BROS. ADVISORS LP | Merus N.V. | 1,160,014 | 7.2% | EDGAR |
| SC 13G | 2017-02-14 | BAKER BROS. ADVISORS LP | Merus N.V. | 1,160,014 | 7.2% | EDGAR |
| SC 13G | 2017-02-10 | Aglaia Oncology Fund B.V. | Merus N.V. | 1,109,145 | 6.9% | EDGAR |
| SC 13G | 2017-01-23 | INCYTE CORP | Merus N.V. | 3,200,000 | 16.6% | EDGAR |
| SC 13G | 2017-01-18 | JOHNSON & JOHNSON | Merus N.V. | 1,195,943 | 7.4% | EDGAR |
| SC 13G | 2016-06-06 | PFIZER INC | Merus N.V. | 1,142,548 | 7.1% | EDGAR |
| SC 13D/A | 2016-06-03 | Cooperatief LSP IV U.A. | Merus N.V. | 1,225,661 | 7.6% | EDGAR |
| SC 13G | 2016-06-03 | Novartis Bioventures Ltd | Merus N.V. | 2,181,320 | 13.6% | EDGAR |
| SC 13D/A | 2016-06-02 | Novo A/S | Merus N.V. | 1,410,417 | 8.8% | EDGAR |
| SC 13D | 2016-05-27 | Sofinnova Venture Partners IX, L.P. | Merus N.V. | 1,401,403 | 9.1% | EDGAR |
| SC 13D | 2016-05-27 | BAY CITY CAPITAL LLC | Merus N.V. | 2,101,320 | 13.1% | EDGAR |
| SC 13D | 2016-05-26 | Novo A/S | Merus N.V. | 1,407,399 | 9.1% | EDGAR |